| Dr Sameer Ali Syed, MD | |
|
3151 W 15th St, Plano, TX 75075 | |
| (214) 817-4225 | |
| (972) 674-2788 |
| Full Name | Dr Sameer Ali Syed |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 14 Years |
| Location | 3151 W 15th St, Plano, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083933089 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LP2900X | Anesthesiology - Pain Medicine | 275245 (New York) | Secondary |
| 207LP2900X | Anesthesiology - Pain Medicine | Q2071 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hunt Regional Medical Center | Greenville, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sameer Syed Md Pa | 6204198575 | 4 |
News Archive
The prospect of the U.S. healthcare system moving from paper to electronic medical records (EMR) has given rise to a host of thorny questions on matters of privacy, security, logistics and more. But according to EMR attorneys at the national law firm of LeClairRyan, the time to start making the switch is now–in part because the federal government will soon finalize important new guidelines on what healthcare providers need to do in order to "go digital."
The use of digital health technologies across health care and drug development has accelerated. A new paper titled "Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective," co-authored by experts across diverse disciplines, highlights how new remote monitoring technologies present a tremendous opportunity to advance digital medicine in health care even further, specifically in Parkinson's disease.
GeckoSystems Intl. Corp. - announced today that during their first annual "Mobile Robots in Motion" conference November 4-5, 2009 they will discuss the new Current Procedural Terminology (CPT) Codes regarding in home medical device monitoring reimbursements.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.
The National Multiple Sclerosis Society awarded Victoria Leavitt, PhD, a $619,618 grant to study predictors of memory decline in MS. Dr. Leavitt, a scientist in Neuropsychology and Neuroscience Research at Kessler Foundation, will use functional magnetic resonance imaging to evaluate a brain marker with predictive value for memory decline.
› Verified 9 days ago
| Entity Name | Sameer Syed Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568984573 PECOS PAC ID: 6204198575 Enrollment ID: O20180326002156 |
News Archive
The prospect of the U.S. healthcare system moving from paper to electronic medical records (EMR) has given rise to a host of thorny questions on matters of privacy, security, logistics and more. But according to EMR attorneys at the national law firm of LeClairRyan, the time to start making the switch is now–in part because the federal government will soon finalize important new guidelines on what healthcare providers need to do in order to "go digital."
The use of digital health technologies across health care and drug development has accelerated. A new paper titled "Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective," co-authored by experts across diverse disciplines, highlights how new remote monitoring technologies present a tremendous opportunity to advance digital medicine in health care even further, specifically in Parkinson's disease.
GeckoSystems Intl. Corp. - announced today that during their first annual "Mobile Robots in Motion" conference November 4-5, 2009 they will discuss the new Current Procedural Terminology (CPT) Codes regarding in home medical device monitoring reimbursements.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.
The National Multiple Sclerosis Society awarded Victoria Leavitt, PhD, a $619,618 grant to study predictors of memory decline in MS. Dr. Leavitt, a scientist in Neuropsychology and Neuroscience Research at Kessler Foundation, will use functional magnetic resonance imaging to evaluate a brain marker with predictive value for memory decline.
› Verified 9 days ago
| Entity Name | Leading Anesthesia Partners Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518453356 PECOS PAC ID: 7416389812 Enrollment ID: O20200109001057 |
News Archive
The prospect of the U.S. healthcare system moving from paper to electronic medical records (EMR) has given rise to a host of thorny questions on matters of privacy, security, logistics and more. But according to EMR attorneys at the national law firm of LeClairRyan, the time to start making the switch is now–in part because the federal government will soon finalize important new guidelines on what healthcare providers need to do in order to "go digital."
The use of digital health technologies across health care and drug development has accelerated. A new paper titled "Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective," co-authored by experts across diverse disciplines, highlights how new remote monitoring technologies present a tremendous opportunity to advance digital medicine in health care even further, specifically in Parkinson's disease.
GeckoSystems Intl. Corp. - announced today that during their first annual "Mobile Robots in Motion" conference November 4-5, 2009 they will discuss the new Current Procedural Terminology (CPT) Codes regarding in home medical device monitoring reimbursements.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.
The National Multiple Sclerosis Society awarded Victoria Leavitt, PhD, a $619,618 grant to study predictors of memory decline in MS. Dr. Leavitt, a scientist in Neuropsychology and Neuroscience Research at Kessler Foundation, will use functional magnetic resonance imaging to evaluate a brain marker with predictive value for memory decline.
› Verified 9 days ago
| Entity Name | Synergy Medical Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538872429 PECOS PAC ID: 8729422894 Enrollment ID: O20240216000254 |
News Archive
The prospect of the U.S. healthcare system moving from paper to electronic medical records (EMR) has given rise to a host of thorny questions on matters of privacy, security, logistics and more. But according to EMR attorneys at the national law firm of LeClairRyan, the time to start making the switch is now–in part because the federal government will soon finalize important new guidelines on what healthcare providers need to do in order to "go digital."
The use of digital health technologies across health care and drug development has accelerated. A new paper titled "Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective," co-authored by experts across diverse disciplines, highlights how new remote monitoring technologies present a tremendous opportunity to advance digital medicine in health care even further, specifically in Parkinson's disease.
GeckoSystems Intl. Corp. - announced today that during their first annual "Mobile Robots in Motion" conference November 4-5, 2009 they will discuss the new Current Procedural Terminology (CPT) Codes regarding in home medical device monitoring reimbursements.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.
The National Multiple Sclerosis Society awarded Victoria Leavitt, PhD, a $619,618 grant to study predictors of memory decline in MS. Dr. Leavitt, a scientist in Neuropsychology and Neuroscience Research at Kessler Foundation, will use functional magnetic resonance imaging to evaluate a brain marker with predictive value for memory decline.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sameer Ali Syed, MD 7668 Eldorado Pkwy Ste 300, Mckinney, TX 75070-5753 Ph: (214) 817-4225 | Dr Sameer Ali Syed, MD 3151 W 15th St, Plano, TX 75075 Ph: (214) 817-4225 |
News Archive
The prospect of the U.S. healthcare system moving from paper to electronic medical records (EMR) has given rise to a host of thorny questions on matters of privacy, security, logistics and more. But according to EMR attorneys at the national law firm of LeClairRyan, the time to start making the switch is now–in part because the federal government will soon finalize important new guidelines on what healthcare providers need to do in order to "go digital."
The use of digital health technologies across health care and drug development has accelerated. A new paper titled "Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective," co-authored by experts across diverse disciplines, highlights how new remote monitoring technologies present a tremendous opportunity to advance digital medicine in health care even further, specifically in Parkinson's disease.
GeckoSystems Intl. Corp. - announced today that during their first annual "Mobile Robots in Motion" conference November 4-5, 2009 they will discuss the new Current Procedural Terminology (CPT) Codes regarding in home medical device monitoring reimbursements.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.
The National Multiple Sclerosis Society awarded Victoria Leavitt, PhD, a $619,618 grant to study predictors of memory decline in MS. Dr. Leavitt, a scientist in Neuropsychology and Neuroscience Research at Kessler Foundation, will use functional magnetic resonance imaging to evaluate a brain marker with predictive value for memory decline.
› Verified 9 days ago
Dr. Monica Ata, MONICA ATA D.O. Anesthesiology Medicare: Medicare Enrolled Practice Location: 5944 West Parker Rd, Suite 400, Plano, TX 75093 Phone: 972-980-0500 | |
Dr. Paul S Dereska, D.O. Anesthesiology Medicare: Medicare Enrolled Practice Location: 3308 Preston Rd, Ste. 350-283, Plano, TX 75093 Phone: 214-471-5975 | |
Tejas Vasant Ozarkar, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5425 W. Spring Creek Parkway, Suite 100, Plano, TX 75024 Phone: 972-596-1059 Fax: 972-612-5410 | |
Ola Yinka, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6009 W Parker Rd # 149-261, Plano, TX 75093 Phone: 214-274-9314 | |
Dr. Matt Ted Gubert, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 400 Chisholm Pl Ste 406, Plano, TX 75075 Phone: 972-588-4541 Fax: 469-304-0139 | |
Dr. Brad Richard Davis, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 801 E Plano Pkwy, Suite 100, Plano, TX 75074 Phone: 972-422-5941 Fax: 972-881-4390 |